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The coincidence of diabetes mellitus and asthma, their probable 
causal relationships and therapeutic opportunities 
Abstract
Both the epidemiological data and the everyday medical practice demonstrate the coincidence of various types of diabetes 
mellitus (DM) in patients with asthma. Specific correlations between the risk of DM in pregnancy, asthma and the consequenc-
es of these diseases to the mother and her baby are also explored. The discussion concerning, on the one hand, the impact of 
asthma-related inflammatory condition on the metabolism of carbohydrates, and, on the other, the presence of chronic hypergly-
cemia and inflammatory markers observed in patients with asthma, is still ongoing. In the case of asthma and type 1 diabetes 
mellitus (T1DM), a correlation with the dysfunction of the immune system and the genetic background has been suggested, and 
in the case of type 2 (T2DM), the vital role of obesity and insulin resistance (IR) to promote excessive proinflammatory immune 
response. The data indicate that both asthma and DM affect mutually their clinical presentations, including the prognostic values 
and therapeutic possibilities. The ongoing controversy concerning the effective and safe anti-asthma and hypoglycemizing ther-
apy does not allow for a definitive therapeutic consensus in this group of patients, despite the suggested role of metformin and 
hyperglycemizing effects of glucocorticoids. Therefore, the objective of the presented paper is a review of the knowledge in the 
field of DM and asthma coincidence, their probable causal relationships and therapeutic opportunities.
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Introduction
In daily medical practice, either pneumologi-
cal or diabetological, we are dealing with patients 
with diabetes mellitus (DM) coexistent with 
asthma. Due to the pathological and therapeutic 
heterogeneity of the types of DM, as well as the 
asthma medications used by the patients, the 
relationship between these diseases is significant 
from both theoretical and practical point of view. 
From the theoretical point of view, the possible 
etiological mechanisms of the coexistence of 
both diseases and the factors influencing their 
mutual course should be sought. Obtaining such 
information, from the practical point of view, may 
allow for the development of diagnostic schemes 
in the direction of DM in patients with asthma, 
determination of the mutual clinical picture, and 
selection of the appropriate therapeutic regimens 
in the case of coexistence of these diseases.
Despite the availability of studies assessing 
the etiopathological relationship between DM 
and asthma, there is still an ongoing discussion 
concerning the impact of inflammatory markers 
associated with asthma on the metabolism of 
carbohydrates. On the other hand, the available 
data suggest a significant effect of the carbohy-
drate metabolism on the presence of inflammation 
in the patients’ organism. These concerns stem 
from the lack of a sufficient number of studies 
exploring the relationship between asthma and 
the development of DM. Currently, practical 
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guidance on the indications to perform diagnos-
tics for DM in asthma patients and the standards 
of hypoglycemizing and asthma therapy in this 
group of patients is also missing.
Therefore, the objective of this work is to sum 
up the knowledge in the field of coexistence of DM 
and asthma, their probable causal relationship, 
as well as taking advantage of the opportunities 
for providing a safe hypoglycemizing and asth-
ma therapy. The presented analysis will seek to 
harmonize the standards of diagnostic and ther-
apeutic management for the coexistence of these 
diseases, or their risk factors.
Epidemiology
DM and its complications represent currently 
an important health problem. In 2017, 424.9 mil-
lion adult patients aged 20–79 years were esti-
mated to have DM, and the data suggest that by 
2045 this number will increase to 628.6 million. 
It should be noted that type 2 (T2DM) is the most 
common type of this disease in adults, occur-
ring in approx. 87–91% of diabetic patients. The 
remaining group consists of patients with type 
1 diabetes mellitus (T1DM) (7–12%) and 1–3% 
of those diagnosed with gestational diabetes 
(GDM), or secondary diabetes resulting from gene 
mutation, other chronic diseases (especially of 
the pancreas), or the used medications. These 
proportions are reversed in children and adoles-
cents, with the predominance of T1DM and the 
number of patients reaching currently over one 
million. It is noteworthy that in this age group, 
due to the epidemics of obesity, the incidence of 
T2DM is continually increasing [1]. Notably, DM 
occurs slightly more frequently in adult men than 
in women. In 2014, the incidence of this disease 
amounted to 9.0% and 7.9%, respectively and, ac-
cording to the predictions, these rates will increase 
to 12.8% (men) and 10.4% (women) in 2025 [2].
The data indicate a slightly lower incidence 
of asthma than that of DM. In 2012, the disease 
was diagnosed in approx. 334 million subjects 
all over the world, and there have been signifi-
cant differences between the assessed countries 
(Austria 21.0% vs China 0.2%) [3]. In contrast 
to DM, the number of asthma cases is believed 
to remain stable, with its rapid growth in the 
developing countries, and a reduction in the in-
cidence in the developed countries. It should be 
noted that male children more often suffer from 
asthma (approx. 20% higher incidence), whereas 
cigarette smoking and obesity are among the main 
risk factors for developing the disease [4].
An increasing number of papers reports 
the coexistence of various types of DM and 
asthma. A meta-analysis of 11 clinical studies 
carried out on a group of more than 550 thou-
sand patients aged 57.23 ± 11.65 years with and 
without asthma showed that patients who have 
been diagnosed with the disease suffer from DM 
more frequently [odds ratio (OR) 1.25, 95% CI 
1.08–1.44, p < 0.00001] [5]. An analysis of 12-year 
follow-up in The Women’s Health Study, conduct-
ed in a group of 38.570 women aged ≥ 45 years 
with asthma/asthmatic symptoms (8.7%), or with 
overlap syndrome [asthma accompanying COPD 
(chronic obstructive pulmonary disease)] (3.2%) 
without DM showed 2472 new T2DM cases. In the 
age- and randomized treatment-adjusted model, 
the presence of asthma and/or COPD was asso-
ciated with a 1.75-fold increased risk of T2DM 
as compared with healthy subjects. Moreover, 
patients with preexisting asthma alone also had 
a higher risk of T2DM than those in the same con-
trol group [the multivariate-adjusted relative risk 
(RR) 1.37, 95% CI 1.20–1.57]. It should be noted 
that the risk was independent of the presence of 
the standard diabetogenic factors, including the 
lack of adequate physical activity, cigarette smok-
ing, the use of hormone replacement therapy, 
consuming excessive quantities of alcohol, the 
family history of DM and hypertension, familial 
hypercholesterolemia and an improper diet [6]. 
A study by Finnish researchers showed that pre-
vious diagnosis of asthma increased the risk of 
subsequent T1DM by 41% (95% CI 1.28–1.54), 
whereas previous diagnosis of T1DM decreased 
the risk of subsequent asthma by 18% (95% CI 
0.69–0.98). It should be emphasized that these 
findings were independent of the relevant risk 
factors, such as age at diagnosis, birth decade, 
sex, the presence of maternal asthma/DM and 
birth-related factors [7]. A similar observation 
was made by Chinese scientists in a group of 
adults, where besides hypertension, myocardial 
infarction and ischemic stroke, DM was featured 
as one of the major diseases coexisting with asth-
ma. In addition, statistical analysis demonstrated 
a significant relationship between the lifestyle 
affecting carbohydrate metabolism [body mass 
index (BMI), smoking, alcohol consumption, ed-
ucational level, watching television and playing 
computer games] and the risk of the development 
of asthma [8].
An observational study based on the use of 
the Austro-German DPV database indicated that 
3.4% of patients below 20 years of age with T1DM 
also had asthma, or received asthma-specific 
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drugs. It is worth noting that patients with T1DM 
and asthma were more often males, were older, 
and had longer DM duration [9]. In turn, a study 
assessing the presence of post-steroid complica-
tions in patients with severe asthma, including 
subjects from two large databases — the Optimum 
Patient Care Research Database (OPCRD) and the 
British Thoracic Society (BTS) Difficult Asthma 
Registry demonstrated that T2DM occurred in 
more patients with severe than with mild/mod-
erate form of asthma (10% vs 7%, OR 1.46, 95% 
CI 1.11–1.91, p < 0.01) [10].
Immunopathology
Asthma is a heterogeneous disease associated 
with the presence of chronic inflammatory condi-
tion, leading to remodeling of the airways. A ma-
jor role in the etiopathogenesis of asthma, in ad-
dition to the presence of a polymorphism of many 
genes responsible for the proper functioning of 
epithelial barriers, innate and acquired immune 
responses (including genes for interleukin 33 
(IL-33), IL1RL1/IL18R1, HLA-DQ, mothers against 
decapentaplegic homolog 3 (SMAD3), IL2RB9, 
zona pellucida binding protein 2 (ZPBP2), GSDMB 
and ORMDL3), is played by dendritic cells and 
Th2 cells, producing, inter alia, IL-4, IL-5 and 
IL-13, and a variety of other cytokines. They all 
play an important role in the maturation and 
survival of eosinophils, their recruitment to the 
pulmonary mucosa, the isotype switching of 
B-cells and the synthesis of immunoglobulin E 
(IgE), which activates the mast cells when bound 
to the appropriate receptors [4, 11]. 
 The etiopathogenesis of the various types 
of diabetes is somewhat less complex, but also 
includes the interaction between different genetic 
and environmental factors resulting in a gradual 
loss of pancreatic β cell mass and/or their proper 
functioning. In the case of T1DM, the variants of 
genes in one large locus– human leukocyte anti-
gen (HLA) are associated with a 50-60% increase 
in the genetic risk for DM, by affecting the binding 
of HLA protein with antigen peptides and antigen 
presentation to T cells. It should be mentioned 
that these are not the only genes involved in the 
development of this disease. It has been suggested 
that there are about ca. 50 such genes, and they 
all contribute, inter alia, to the modulation of the 
regulation of immunity. In addition, the suggested 
association between the environmental factors, 
such as infections (mainly viral), nutrients (glu-
ten) and the autoimmune process and the risk of 
the development of T1DM should be emphasized. 
Notably, in this situation, the presence of autoan-
tibodies reflects the basic immune response of T 
and B cells to the β cell antigens [12].
Obesity and insulin resistance (IR) are the two 
main causal factors of T2DM. In the recent years, 
a close correlation between the presence of excess 
fat and the functioning of the immune system has 
been found. This system has been demonstrated 
to have a significant impact on, inter alia, differ-
entiation of adipocytes and prevention of ectopic 
deposition of lipids. The dysfunctional adipose 
cells (due to caloric overload) were found to be 
characterized by multiple anomalies (including 
excessive production of leptin and reduced pro-
duction of adiponectin, hypoxia and excessive 
deposition of the cellular matrix — collagen and 
elastin). These changes entail a variety of conse-
quences, including initiation and/or promotion 
of the immune response in the form of persistent 
excessive number of immune cells producing 
proinflammatory cytokines [13]. On the other 
hand, a study by Carpio et al. did not observe 
the presence of breathlessness sensation during 
exercise to be dependent on the peak respiratory 
rate, peak respiratory CO2 equivalent, as well as 
the proinflammatory cytokines, such as IL-6 and 
IL-1β in sera [14]. Some authors divide obese 
patients with asthma into two phenotypes: early 
atopic Th2-high type asthma with more severe 
bronchial hyperreactivity and higher concentra-
tion of IgE, where asthma is complicated by the 
presence of obesity and late, non-atopic Th2-low 
asthma, occurring mainly in women whose devel-
opment of asthma is the consequence of obesity 
and is associated with lower incidence of atopy, 
bronchial hyperreactivity, airway obstruction and 
the number of exacerbations [15]. 
The link between obesity, intestinal microbi-
ota and diseases related to the immune system, 
including asthma, is becoming increasingly 
popular. This mechanism also seems to be not 
understood completely, but there are indications 
that besides the involvement of IgA and calpro-
tectin produced by the mucous membranes, the 
exposure to lipopolysaccharides (LSP), produc-
tion of short-chain fatty acids (SCFA), bile acids 
and intestinal microflora products are involved 
in this process as well [16]. In a study by Cani 
et al., the animal model demonstrated that mice 
fed with high-fat carbohydrate-free diet (72% fat, 
28% protein and < 1% carbohydrates) had higher 
concentrations of LPS. Such a diet was observed 
to change drastically not only the intestinal flo-
ra by a significant reduction in the number of 
Gram-positive and Gram-negative bacteria (Lacto-
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bacillus spp., Bifidobacterium spp., and Bacteroi-
des-Prevotella spp.), associated with an increase 
in the permeability of the intestines caused by 
decreased expression of epithelial tight junction 
proteins such as ZO-1 and Occludin (an integral 
plasma-membrane protein located at the tight 
junctions), but also the concentrations of mRNA 
PAI-1, IL-1, tumor necrosis factor-α (TNF-α) and 
F4/80 in the visceral (mesenteric) adipose tissue. 
The above correlation was abolished completely 
by institution of 4-week antibiotic treatment 
leading to substantial reduction of inflammatory 
markers in the group fed with the high-fat diet. 
Moreover, the used high-fat diet was proven to 
be associated with an increase in blood glucose, 
which was reduced by the use of antibiotic 
therapy. Similar observations apply to the car-
bohydrate diet inducing insulin secretion, the IR 
indicator, weight gain, total energy consumption 
and the weight of visceral and subcutaneous 
adipose tissue [17].
On observation of the patients already diag-
nosed with T2DM, the presence of irregularities 
in the immune system function, associated with 
the onset and persistence of a chronic inflam-
matory condition responsible for disturbances 
of inflammation transduction, is also notable. 
For example, in a study conducted by Danona 
et al., it was demonstrated that the expression 
of inflammatory markers such as IL-4, matrix 
metallopeptidase 9 (MMP-9), LIGHT (tumor ne-
crosis factor superfamily member 14, TNFSF14), 
chemokine receptor type 2 (CCR-2) and plasma 
concentrations of nitric oxide metabolites (NOM) 
was significantly higher in obese patients, includ-
ing those with T2DM as compared with healthy, 
nonobese subjects. It was also found that, except 
for the concentrations of NOM, these values cor-
relate with The Homeostatis Model Assessment 
— Insulin Resistance (HOMA-IR) and BMI [18]. 
In turn, the study by Sindhu et al. proved that 
patients suffering from asthma and T2DM have 
a higher concentration of monocyte chemoat-
tractant protein-1 (MCP-1) compared to those 
with and without one of the above diseases, and 
the concentration of that marker correlated with 
other exponents of inflammation and respiratory 
tract remodeling, such as IFN-α2, IL1RA, IL-10, 
Fractalkine/CX3CL-1 and vascular endothelial 
growth factor (VEGF). Slightly different correla-
tions of that marker were found in the compared 
groups of patients with T2DM and asthma (in 
that group correlation with IL-3, IL-6, IL-9, MIP-
1α/CCL-3, MIP-1β/CCL-4, GROα/CXCL-1 i BMI) 
and those with asthma without T2DM (correlation 
with IL-1β, IL1RA, MDC/CCL-22, IP-10/CXCL-10, 
GM-CSF, FGF-2, PDGF-AA, PDGF-BB and glycated 
hemoglobin — HbA1c) [19]. 
 In the case of patients with T1DM and asth-
ma, the etiopathogenetic link seems to be stronger 
than in the type of carbohydrate metabolism dis-
orders described above, but there are still contro-
versies. For example, the study by Vaseghi et al. 
showed a significantly lower expression of T-bet 
and IFN-γ genes in T1DM patient group compared 
with subjects without DM (p < 0.05). There was, 
however, no significant relationship between 
the expression of GATA-3 and the presence of 
DM, while a significant increase in IL-4 mRNAs 
in peripheral blood mononuclear cells (PBMCs) 
and plasma concentrations of this cytokine (p < 
0.001) was reported in the group of patients with 
T1DM (p < 0.05), as well as decreased concentra-
tion of another inflammatory marker — IFN-γ (p 
< 0.001) [20]. In the study by Peters et al., it was 
found, however, that notwithstanding the severity 
of asthma (severe and non-severe), the increased 
level of IL-6 correlates with the value of BMI (p < 
0.0001) and the presence of DM (p = 0.04) [21].
Clinical picture
Clinical data suggest, however, that DM is 
one of the least common chronic diseases con-
comitant in patients with asthma, including 
controlled/uncontrolled cases. It has been also 
found that DM is slightly more frequent in asthma 
patients with correctly controlled disease than in 
those with poor asthma control (12.5% vs 11.1%), 
as well as in obese ones (18.6 vs 13.9, respective-
ly) [22]. It is notable that the presence of obesity 
in patients with asthma is associated with more 
severe symptoms, destabilization and loss of 
control of the disease, as well as deterioration of 
the quality of life, a different response to the med-
ication to control the disease, the development of 
steroid resistance and the absence of eosinophilic 
inflammation [23]. It has also been shown that the 
diagnosis of IR is associated, like in the case of 
obesity, with a significantly increased presence of 
wheezing incidents (OR 1.87, 95% CI 1.38–2.54) 
and asthma-like symptoms (OR 1.61, 95% CI 
1.23–2.10). This correlation has also been proven 
to be stronger in the case of IR than of obesity and 
independent of the gender of the patient [24]. It 
is also worth mentioning that obesity can cause 
shortness of breath on exertion by reducing the 
functional residual capacity of the respiratory 
reserve volume. Obesity in adults, particularly 
in women, may be associated with treatment- 
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-resistant asthma with less eosinophilic and more 
neutrophilic sputum profile [25].
In daily clinical practice, the existence of an 
association between the presence of DM and the 
risk of pneumococcal diseases, including com-
munity-acquired pneumonia (CAP) and invasive 
pneumococcal disease (IPD), in adult patients, 
especially those aged ≤ 40 years without comor-
bidities, is also worth keeping in mind. It has been 
shown that this risk increases with the duration 
of DM and inadequate glycemic control [26].
In the GEIRD (Gene Environment Interactions 
in Respiratory Diseases) study conducted on 
patients aged 45-64 and 65-84 years, including 
individuals with T2DM, no significant differences 
as to the incidence of asthma were observed in 
the analyzed groups of patients with and without 
DM. It was noticed, however, that people with DM 
reported slightly more frequently dyspnea limiting 
the walking pace (modified MRC grade 2 dyspnea) 
in the respective age groups (7.9% vs 23%, p < 
0.001 and 13.7% vs 30.9%, p < 0.001). Compared 
to the general population, patients with DM aged 
45–64 years complained more frequently of chron-
ic cough/presence of phlegm (p = 0.017) [27].
With respect to patients with T1DM, taking 
into account the previously cited review of the 
DPV database, it has been suggested that in-
dividuals with this type of DM suffering from 
asthma, compared to subjects without asthma, 
are at a similar age at DM diagnosis with similar 
prevalence of overweight and obesity, diabetic 
ketoacidosis, as well as similar values of blood 
pressure and lipid profile. It has also been shown 
that patients with T1DM and asthma more often 
use continous subcutaneus insulin infusion, more 
often have hypoglycemic coma, with almost the 
same average value of HbA1c (8.28 ± 1.8% vs 
8.3 ± 1.7%, p = 0.77). It seems to be associated 
with higher doses of insulin that they have to use 
(0.88 0.3 vs 0.84 0.3 U/kg, p < 0.01) and specific 
anti-asthma drugs (62% — asthmatics, including 
28% — requiring inhaled glucocorticoids — IGCs, 
24% — sympathomimetics, 6% — leukotriene 
receptor antagonists and 4% — other nonspecific 
medications). It should also be noted that the 
subjects using sympathomimetics, compared to 
patients using IGCs and leukotriene modifiers, 
had a higher HbA1c (8.42 ± 1.83% vs 8.18 ± 
1.55% and 8.42 ± 1.55% vs 7.97 ± 1.14%). Di-
abetic ketoacidosis occurred more frequently 
in subjects using sympathomimetics than IGCs 
(8.5 vs 4.8 per 100 patient-years, p = 0.0117) [28].
When discussing the clinical problems asso-
ciated with the presence of asthma with DM, the 
impact of these diseases on basic lung function 
tests should also be mentioned. In their study, 
Klein et al. demonstrated that patients with DM 
had lower mean forced expiratory volume in 
1 second (FEV1), lower forced vital capacity (FVC) 
and higher dyspnea scores than those without 
DM regardless of the presence of chronic lung 
disease (LD) such as asthma, chronic bronchitis 
or emphysema [FEV1 3.00 (95% CI 2.96–3.04) 
vs 3.10 (3.09– 3.11) L, p < 0.01, for participants 
without LD and 2.86 (2.79–2.93) vs 2.95 (2.92–
2.99) L, p < 0.05, for participants with LD, FVC 
3.62 (3.59–3.66) vs 3.81 (3.79–3.83) L, p < 0.001, 
for participants without LD and 3.56 (3.48–3.63) 
vs 3.74 (3.70–3.77) L, p < 0.001, for partici-
pants with LD; dyspnea score 0.60 (0.49–0.71) vs 
0.41 (0.34–0.49), p < 0.001, for participants with-
out LD and 1.25 (0.94–1.55) vs 0.77 (0.54–1.00), p 
< 0.001, for participants with LD]. There was no 
significant effect of coexistence of these diseases 
on CRP activity. It has been shown, however, that 
the aforementioned indicators of lung damage 
correlate in patients with T2DM with the value of 
albumin-to-creatinine ratio (ACR), and the value 
of FVC was inversely proportional to the HbA1c 
percentage in patients without LD (a reduction of 
FVC values of 16 ± 7 L per 1% increase in HbA1c). 
It should be mentioned that this observation ap-
plies to the Spanish/Latino cohort and suggests 
that alveolar-capillary microangiopathy-related 
mechanisms play a role in this association [29]. 
The above study provides the confirmation of the 
earlier observations concerning the differences in 
the FVC, FEV1 and diffusing capacity for carbon 
monoxide (TL,CO) values in spirometry in patients 
with and without DM, in whom significant differ-
ences in the tested aerobic capacity parameters 
were found. However, this study indicates the 
presence of a controversy as to the ethnic dif-
ferences, pointing out the Spanish/Latino race 
rather than the Caucasians or Afroamericans as 
more susceptible to pulmonary diabetic compli-
cations [30].
 Referring to the complications and comor-
bidities, the results of the recently published 
Swedish study demonstrating that cessation of 
cigarette smoking in patients with asthma con-
tributes to a reduction of high level of cardiovas-
cular risk factors, including DM (OR 3.87, 95% 
CI 1.04–14.4, p = 0.04) [31]. 
Treatment
The everyday clinical practice as well as the 
research data indicate the presence of a contro-
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versy concerning the “carbohydrate” safety of 
anti-asthma medications and the selection of 
hypoglycemizing drugs in patients with asthma 
and DM.
The debate on the diabetic safety of anti-asth-
ma medications concerns mainly GCs. A litera-
ture review conducted by American scientists 
points to 4-fold higher risk of developing DM in 
patients who chronically use this group of drugs 
[32]. Sullivan et al., based on the MarketScan® 
data set, found that the use of oral glukocortico-
steroids (OGCs) four times per year or more was 
associated with a significant risk for the develop-
ment of T2DM (OR 1.28, 95% CI 1.13–1.449, p 
< 0.01). Such a risk was, however, not reported 
among the patients using this group of drugs less 
often — 1–3 times per year (OR 1.056, 95% CI 
1.015–1.098) [33].
A retrospective study conducted by British 
researchers using a UK-based Clinical Practice 
Research Datalink (CPRD) on over 60 thousand 
patients with severe asthma (stage 4 or 5, ac-
cording to GINA) also confirmed that the use 
of OGCS involved a risk of developing DM in 
this group of patients [1.04 events per 1000 per-
son-(28 day)-periods], and this increase occurred 
also with small doses (> 0-2.5 mg/day (HR 1.20, 
95% CI 1.11–1.30) and correlated with an increase 
in the administered OGCs dose (for > 2.5 mg/day 
— HR 1.77, 95% CI 1.44–2.01) [34]. Analyzing 
other drugs used in the treatment of asthma, it 
should be noted that there are no detailed data to 
evaluate the effect of cholinolytics on carbohy-
drate metabolism. In the case of patients requiring 
therapy with anti-IgE antibodies, there have been 
reports suggesting a negative effect of omalizumab 
on metabolic control of DM, and a positive one 
of mepolizumab [35].
The choice of drugs in patients with asthma is 
mainly dependent on the type of DM. In the case 
of T1DM, the drug of choice is insulin adminis-
tered in different therapeutic schedules. A study 
on a small group of 24 patients with more severe 
asthma exacerbations, requiring the use of OGCs 
and possibly insulin therapy in the infusion pump 
or subcutaneously, showed that, regardless of the 
route of insulin administration, hyperglycemia is 
associated with the prolongation of the necessary 
time of hospitalization (8.2 ± 2.4 and 10.2 ± 
5.2 vs 5.8 ± 1.9 in the group not requiring insulin) 
[36]. Ahmadizar et al., during their 5-year fol-
low-up study, found a significantly higher rate of 
the use of asthma medications in patients after the 
diagnosis of T1DM (23.2% vs 18.3% in the control 
group). However, they did not observe a statisti-
cally significant difference between patients with 
and without DM in the application of the specific 
anti-asthma medications, except for short-acting 
muscarinic antagonists, more often used in the 
T1DM patient group (5.5% vs 0.62% of the control 
group). It is noteworthy that the frequency of use 
of anti-asthma medications decreased over time, 
and the peak of the phenomenon was observed 
in the first year after the onset of DM. It is also 
worth mentioning that asthma exacerbations 
reached a peak after the first year, both in the 
case of T1DM (7.8 per 1000 population per year) 
and the reference group (6.8 per 1000 population 
per year) [37].
In the group of patients with T2DM, the sit-
uation seems to be more complicated, because 
the availability of hypoglycemizing drugs is 
increasing. According to the diabetological rec-
ommendations, the drug of choice is metformin 
(MET), which each patient without contraindica-
tions and tolerant to this medicine should receive 
[38]. A study by Li et al. in 1332 asthma and DM 
patients (including 33.3% of the patients on MET) 
demonstrated that the use of MET reduces the risk 
of hospitalization for asthma (OR = 0.21, 95% CI 
0.07–0.63) and the risk of asthma exacerbations 
(OR = 0.39, 95% CI 0.19–0.79), but not emergen-
cy room visits (OR = 0.62, 95% CI 0.26–1.44). It 
was found that the subjects treated with MET 
use more often short-acting β2-agonists (30.2% vs 
24.1%, p < 0.05) and methylxanthine (42.8% vs 
32.8%, p < 0.01). It should be noted that patients 
who used MET less frequently required insulin 
(6.1% vs 13.5%, p < 0.01) and hospitalization 
for asthma (0.9% vs 3.3%, p < 0.01) than those 
not treated with MET [39]. It has been suggested 
that the mechanism underlying these properties 
of MET beneficial to protect the lungs is LPS-
evoked TLR4 activation and the protective effect 
can be related to the activation of AMPK [40]. In 
contrast to insulin therapy, it was concluded that 
the use of MET by patients with DM reduces the 
risk of the development of asthma (for insulin OR 
2.23, 95% CI 1.52–3.58, for MET OR 0.75; 95% CI 
0.60–0.95, respectively) [41].
In the case of patients with T2DM and coro-
nary heart disease coexisting with asthma, the use 
of pioglitazone in this group was demonstrated to 
improve the clinical course of DM and its proper 
control, reduce inflammation and ameliorate the 
epithelial function [42]. A study carried out with 
the use of pioglitazone in the group of 23 patients 
did not confirm the difference in the amount of 
exhaled nitric oxide, asthma control and lung 
function during the 12-week administration of 
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the drug (the median airway reactivity, measured 
by PC20 methacholine was 1.99 (IQR 3.08) and 
1.60 (5.91) mg/mL in the placebo and pioglita-
zone group at the baseline, and 2.37 (15.22) and 
5.08 (7.42) mg/mL after 12 weeks, p = 0.38) [43]. 
In turn, a 12-week study conducted on a group 
of 68 patients with mild asthma (with 55 patients 
ultimately assessed) showed that the use of this 
drug in the dose of 30 mg for 4 weeks, and then 
45 mg for 8 weeks, does not significantly affect the 
FEV1 value (0.014 L, 95% CI 0.15–0.12, p = 0.84), 
as well as the assessed secondary endpoints such 
as mean peak expiratory flow (PEF), scores on the 
Juniper Asthma Control Questionnaire (ACQ) and 
Asthma Quality of Life Questionnaire (AQLQ), 
fractional exhaled nitric oxide (FeNO), bronchial 
hyperresponsiveness (PD20), induced sputum 
counts, and sputum supernatant interferon gam-
ma-inducible protein-10 (IP-10), VEGF, monocyte 
chemotactic protein-1 (MCP-1), and eosinophil 
cationic protein (ECP) levels [44]. 
A retrospective, observational cohort study 
conducted on the basis of American commercial 
databases, covering the years 2006–2014 and pa-
tients with T2DM and asthma, demonstrated that 
the use of the DPP4 inhibitors, such as alogliptin, 
linagliptin, saxagliptin, sitagliptin or mixed 
products containing these agents for a year did 
not affect significantly the risk-domain asthma 
control (RDAC), defined as no asthma hospital-
izations, no lower respiratory tract infections, 
and no OGCs prescriptions (OR 1.05, 95% CI 
0.964–1.147), total control AS (OR 1.04, 95% CI 
0.956–1.135), stability of the therapy (OR 1.04, 
95% CI 0.949–1.115) and the number of severe 
exacerbations (mean = 0.32 vs 0.34 exacerbations 
per subject-year, respectively; p = 0.064) [45].
A study by Toki Si et al. carried out on an 
animal model showed that liraglutide used for 
two days before exposure to Alternaria alterna-
ta — an airborne allergen responsible for severe 
exacerbations of asthma – reduces the number 
of lung epithelial cells expressing IL-33 and the 
level of IL-33 expression by individual cells as 
well as the level of IL 33 in BAL fluid. It should 
be noted that IL-33 is one of the most consis-
tently associated gene candidates for asthma 
identified by GWAS. Studies in animal and 
human cells have confirmed the importance of 
IL-33 in inducing type-2 cytokine production 
from both group 2 innate lymphoid cells (ILC2) 
and Th2 cells. There was, however, no signifi-
cant correlation between the use of liraglutide 
and reduction of lactate dehydrogenase (LDH) 
activity in BAL fluid, extract-induced CysLT and 
PGD2 levels. Further, a GLP-1R agonist signifi-
cantly decreased the number of ILC2 expressing 
IL-5 and IL-13, the lung protein expression of 
type-2 cytokines and chemokines, the number of 
perivascular eosinophils, the mucus production, 
and the airway responsiveness compared with 
vehicle treatment. GLP-1R agonist treatment in-
stituted one day after the first Alternaria extract 
challenge also significantly decreased eosinophil-
ia and type-2 cytokine and chemokine expression 
in the airway after 4 days following Alternaria 
extract challenge [46]. 
Pregnancy
The coincidence of asthma and GDM is still 
being discussed. In a study by Iranian scientists, 
a higher prevalence of GDM was found in a group 
of patients with asthma (adjusted OR 2.64, 95% CI 
1.45–4.78). Such a correlation was not observed in 
the case of DM diagnosed prior to pregnancy (4% 
vs 2.6%) [47]. The data coming from the Finnish 
Medical Birth Register (MBR) (over 1 million 
children followed up within 7 years after birth) 
indicate the predictive value of the presence of 
DM in the mother for the later application of 
anti-asthma medications in children born be-
tween 32-33 weeks of gestation (HR 1.62, 95% 
CI 1.02–2.58) and/or between 34–36 weeks (HR 
0.78, 95% CI 0.63–1.11) [47].
Data from the Quebec Asthma and Pregnancy 
Database (QAPD) based on a cohort of pregnant 
patients with asthma indicate that the use of in-
haled GCs (IGCs) is not associated with the risk 
of GDM, regardless of whether the patients use 
LABA additionally. There was also no significant-
ly greater risk in the case of average IGCS doses 
without LABA compared to low IGCs doses used 
with LABA, and this risk was comparable in the 
groups of patients who used high IGCs doses 
without LABA or average IGCs doses with LABA 
[48]. A meta-analysis carried out in 14 European 
countries with the participation of 85,509 chil-
dren born, assessing the presence of wheezing 
of various severity (at least one, or recurrent 
episodes in the offspring within 12-24 months 
after birth) showed no relationship between this 
clinical symptom and the presence of GDM. It 
should be emphasized that in the case of recur-
rent wheezing, aRR of 1.25 was obtained (95% CI 
0.86–1.79) [49]. On the other hand, data from the 
Swedish Hospital Discharge Register evidence an 
increased risk of developing asthma in children 
over 2 years of age whose mothers had GDM (OR 
1.20, 95% CI 1.02–1.42) [50].
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Discussion
Epidemiological studies indicate a signif-
icant relationship between the different types 
of diabetes and bronchial asthma. Regardless 
of the pathomechanism leading to chronic hy-
perglycemia, it has been found to be associated 
with the activation of the inflammatory response 
that is closely correlated with the presence of 
asthma and its severity. Due to that correlation, 
each patient diagnosed with asthma should also 
be diagnosed for diabetes. Currently, there are 
no hypoglycemizing therapeutic standards for 
patients with concurrent asthma and DM, due to 
the controversy concerning the cause and effect 
relationship between the anti-asthma medications 
and hyperglycemia. In this case, metformin is still 
the drug of choice, but high hopes are associated 
with the novel hypoglycemizing drugs, such as 
DPP4 inhibitors.
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